Sapient launches DynamiQ Normal Human Tissue Proteomics Atlas. DynamiQ proteomics atlas maps protein expression across normal tissues to improve target prioritisation and safety assessment 16 Jun 2026 Product news. Sapient has launched the DynamiQ(TM) Normal Human Tissue Proteomics Atlas, a comprehensive reference map of protein expression, signaling activity, cell surface accessibility, immune biology, and resistance pathways across more than 12,000 proteins in diverse normal human tissues. The atlas enables drug development teams to systematically evaluate where therapeutic targets are expressed in normal human organs, quantify expression relative to tumor or diseased tissue, and identify organs at risk for on-target, off-tissue toxicity, supporting safer and more effective target selection decisions. Comprehensive proteomics atlas of normal human tissue biology. The DynamiQ Normal Human Tissue Proteomics Atlas provides drug developers with a proteome-wide view of normal human biology across more than 15 tissue types, including heart, liver, lung, kidney, and other primary organs commonly associated with dose-limiting toxicities. By enabling direct queries of target protein expression across these tissues, the atlas helps teams quantify tumor-to-normal expression ratios and rank-order candidate targets based on their potential therapeutic index. Beyond expression levels, the atlas incorporates baseline signaling, immune, and resistance pathway data to reveal organ-level vulnerabilities and potential immune-related adverse events. This integrated view of protein abundance, activation state, and biological context is designed to support proactive evaluation of safety liabilities before programs advance into clinical development. By integrating multiple proteomics modalities, the atlas offers a unified framework for understanding how therapeutic targets behave in normal human tissues, helping teams anticipate safety risks and refine their development strategies. Multi-dimensional proteomics profiling across 12,000+ proteins. Sapient uses its mass spectrometry-based proteomics platform to profile each normal human tissue across multiple biological dimensions: * Global protein expression across more than 12,000 protein groups via DiscoverySeek(TM) * Cell surface protein expression via SurfaceSeek(TM) * Phosphorylation-driven signaling pathway activity via SignalingSeek(TM) * Immune cell composition and activation states via ImmuneSeek(TM) * Baseline survival and stress response pathways via ResistanceSeek(TM) Through this comprehensive proteome-wide characterization, the DynamiQ Normal Human Tissue Proteomics Atlas reduces reliance on indirect proxy measurements of protein levels, such as RNA expression databases or single-cell RNA sequencing data. Instead, it delivers direct and diverse protein quantification to inform target selection, safety assessment, and translational strategy. Enabling earlier, data-driven safety and target selection decisions. By providing a detailed map of protein expression and activity in normal tissues, the DynamiQ Normal Human Tissue Proteomics Atlas allows researchers to identify organs at risk for toxicity, evaluate potential immune-related adverse events, and prioritize targets with more favorable safety profiles. This supports more informed decision-making from early discovery through to clinical development. Flexible access models for biopharma and translational research teams. The DynamiQ Normal Human Tissue Proteomics Atlas is available through flexible data licensing and proteomics services models. Options include data access for specific targets of interest, integration of atlas data with internal workflows, and custom proteomics studies using client-provided samples. These access models are designed to support a wide range of applications, from early-stage target discovery and validation to IND-enabling safety studies and clinical development programs. "This atlas does not simply catalog which proteins are present in normal tissues - it reveals how proteins are regulated, activated, and organized across normal human biology," said Dr. Mo Jain, Founder and Chief Scientific Officer at Sapient. "Unlike transcriptomic databases or low-plex immunohistochemistry, we are delivering direct and diverse protein measurements across the proteome - encompassing abundance, surface accessibility, signaling state, immune context, and resistance pathway biology - as a comprehensive reference framework that can be applied from early discovery to target selection, IND-enabling programs, and clinical development." Want the latest science news straight to your inbox? Become a SelectScience member for free today>>. Frequently asked questions. How does Sapient's DynamiQ Normal Human Tissue Proteomics Atlas support safer drug development? The DynamiQ Normal Human Tissue Proteomics Atlas enables drug development teams to systematically evaluate where therapeutic targets are expressed in normal human organs, quantify tumor-to-normal expression ratios, and identify organs at risk for on-target, off-tissue toxicity. This proteome-wide view supports more informed target selection and safety decisions from early discovery through clinical development. What proteomics modalities power the DynamiQ Normal Human Tissue Proteomics Atlas? Sapient uses a mass spectrometry-based proteomics platform to profile normal human tissues across multiple dimensions: DiscoverySeek(TM) for global protein expression, SurfaceSeek(TM) for cell surface proteins, SignalingSeek(TM) for phosphorylation-driven signaling, ImmuneSeek(TM) for immune cell composition and activation, and ResistanceSeek(TM) for baseline survival and stress response pathways. How can biopharma teams access the DynamiQ Normal Human Tissue Proteomics Atlas for translational research? The DynamiQ Normal Human Tissue Proteomics Atlas is available through flexible data licensing and proteomics services. Biopharma and translational research teams can license data for specific targets, integrate atlas data with internal workflows, or commission custom proteomics studies using client-provided samples, supporting applications from target discovery to IND-enabling safety and clinical development.

Sapient, a multi-omics data generation company, has launched its Tumor Protein Mapping Platform, comprising four mass spectrometry-based proteomics workflows designed to characterise functional tumour biology. The platform includes SurfaceSeek, SignalingSeek, ImmuneSeek and ResistanceSeek, each optimised for fresh-frozen and FFPE human tumour samples. SurfaceSeek measures proteins on tumour cell surfaces to identify druggable targets for antibody-drug conjugates, T-cell engagers and radioligand therapies. The additional workflows map tumour signalling pathways, immune microenvironment and therapeutic resistance mechanisms. The workflows can be applied retrospectively to archived tissue repositories, enabling analysis of previously inaccessible functional tumour biology. All four workflows are available as standalone services or in combination for integrated tumour characterisation. The platform is now available to biopharma sponsors.